Core Viewpoint - Meta (META) is considered a "Strong Buy" despite a 10% decline in share price since early September [1] Group 1: Company Background - The analysis is conducted by a Chief Financial Officer (CFO) with over a decade of experience in finance, particularly in the oilfield and real estate industries [1] - The CFO has led numerous complex due diligence efforts and M&A transactions both domestically and internationally [1] Group 2: Investment Insights - The CFO has developed a keen interest in equity research and analysis of public companies, providing equity research services for a Dubai-based family office with over $20 million in assets under management [1] - The expertise in finance allows for valuable insights and recommendations for informed investment decisions [1] Group 3: Analytical Skills - The CFO prides on the ability to analyze financial statements, evaluate market trends, and identify key drivers of growth in different industries [1] - There is a strong passion for staying updated on the latest developments and trends in the equity research industry, with a commitment to continuing education and professional development [1]

The shares got caught up in the artificial-intelligence panic after hitting a record high earlier in the day. ...

Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or perfo ...

WINNIPEG, Manitoba, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV:KNE) (the "Company", "Kane" or "Kane Biotech") announces that today it has completed its previously announced non-brokered private placement offering (the "Offering") of common shares of the Company ("Shares").At the closing of the Offering, Kane issued 14,000,000 Shares at a price of $0.05 per Share for gross proceeds of $700,000 to an insider of the Company.The net proceeds of the Offering will be used for working capital and ge ...

Core Points - Kane Biotech Inc. has completed a non-brokered private placement offering of common shares, issuing 14,000,000 shares at a price of $0.05 per share, resulting in gross proceeds of $700,000 [2] - The net proceeds from the offering will be allocated for working capital and general corporate purposes [2] - The transaction is classified as a "related party transaction" under Multilateral Instrument 61-101, and the company is exempt from formal valuation and minority approval requirements [3] Company Overview - Kane Biotech is focused on developing innovative wound care treatments that target biofilms, which contribute to antibiotic resistance in wounds, leading to serious clinical outcomes and high costs [5] - The company's products, including revyve® Antimicrobial Wound Gel and revyve® Antimicrobial Wound Gel Spray, have received US FDA 510(k) clearance and Health Canada approval [5]

The financial calendar for Schouw & Co. for 2026 is as follows: 5 March 2026Release of Annual Report 202516 April 2026Annual General Meeting21 April 2026Expected payment of dividend for 20251 May 2026Release of Q1 2026 interim report14 August 2026Release of Q2 2026 interim report6 November 2026Release of Q3 2026 interim report Resolution proposals from shareholders to be considered at the annual general meeting to be held on 16 April 2026 must be received by the company on or before Wednesday, 4 March 2026 ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Considering buying VVV stock? Here’s what analysts think: Read This Next: Photo via Shutterstock ...

One interpretation of options market pricing by Goldman Sachs, says stocks won't be tugging the same way next year. ...

If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!Shares of Medline ( MDLN ) have seen spectacular first-day gains, with shares trading up a third as investors are wildly upbeat and optimistic about the potential for this huge healthcare business ...

The oil and gas industry is capital-intensive. Upstream exploration and production companies are the most sensitive to fluctuations in oil and gas prices. Midstream companies, which transport and store hydrocarbons, tend to have less price sensitivity due to long-term contracts but are incredibly capital-intensive and depend on growing demand to justify infrastructure spending. Similarly, the margins of downstream refining and marketing companies can fluctuate based on input costs, such as oil prices and th ...